Physician profile
Samuel D Allen
NPI 1649253444
$3,981.73
in general payments reported to CMS, 2019-2025
20 companies · $323 in 2025
The $323 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $24.99 · 2021: $427 · 2022: $695 · 2023: $1,125 · 2024: $676 · 2025: $323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,724 · Consulting Fee: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,724.25 |
| Consulting Fee | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beaver-Visitec International, INC. | $750.00 | 2022-2023 | |
| Allergan, INC. | $491.85 | 2019-2022 | |
| Abbvie INC. | $449.26 | 2024-2025 | |
| Alcon Vision LLC | $435.26 | 2019-2025 | Eysuvis, Hydrus Microstent, Argos |
| Oyster Point Pharma, INC. | $362.88 | 2022-2024 | Tyrvaya |
| Aerie Pharmaceuticals, INC. | $312.99 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $242.75 | 2019-2025 | Cequa |
| Horizon Therapeutics Plc | $230.67 | 2022-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $145.02 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Amgen INC. | $129.61 | 2024-2025 | Tepezza, Uplizna |
| Novartis Pharmaceuticals Corporation | $79.65 | 2019-2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $77.90 | 2019-2021 | |
| Sight Sciences, INC. | $51.30 | 2021-2022 | |
| Samsara Vision | $49.45 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $42.77 | 2024 | Xdemvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $40.43 | 2021 | |
| Vyera Pharmaceuticals, LLC | $35.22 | 2021 | |
| Ocular Therapeutix, INC. | $20.17 | 2024 | Dextenza |
| Shire North American Group INC | $20.00 | 2019 | |
| Thea Pharma INC. | $14.55 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.